Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter A Milligan

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Clinical Pharmacology and Therapeutics|October 28, 2020
Model Informed Drug Development: Collaboration Through A Common FrameworkRichard J Anziano, Peter A Milligan
British Journal of Clinical Pharmacology|January 30, 2004
Assessment of the relative in vivo potency of the hydroxylated metabolite of darifenacin in its ability to decrease salivary flow using pooled population pharmacokinetic-pharmacodynamic dataThomas Kerbusch, Peter A Milligan, Mats O Karlsson
Antimicrobial Agents and Chemotherapy|December 17, 2008
Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studiesMats O Karlsson, Irja Lutsar, Peter A Milligan
British Journal of Clinical Pharmacology|March 7, 2002
A population pharmacokinetic analysis of sildenafil citrate in patients with erectile dysfunctionPeter A Milligan, Scott F Marshall, Mats O Karlsson
British Journal of Clinical Pharmacology|November 18, 2003
Population pharmacokinetic modelling of darifenacin and its hydroxylated metabolite using pooled data, incorporating saturable first-pass metabolism, CYP2D6 genotype and formulation-dependent bioavailabilityThomas Kerbusch, Ulrika Wählby, Peter A Milligan, et al.
British Journal of Clinical Pharmacology|September 18, 2004
Models for time-varying covariates in population pharmacokinetic-pharmacodynamic analysisUlrika Wählby, Alison H Thomson, Peter A Milligan, et al.
CPT: Pharmacometrics & Systems Pharmacology|July 14, 2023
Model-informed drug development of autologous CAR-T cell therapy: Strategies to optimize CAR-T cell exposure leveraging cell kinetic/dynamic modelingAnna M Mc Laughlin, Peter A Milligan, Cassian Yee, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|June 13, 2008
A non-parametric method to analyse time-course of effect in the absence of pharmacokinetic data: application to inhaled bronchodilatorsBalaji M Agoram, Peter A Milligan, Piet H van der Graaf
Cancer Chemotherapy and Pharmacology|July 23, 2015
Modeling and simulations relating overall survival to tumor growth inhibition in renal cell carcinoma patientsLaurent Claret, Francois Mercier, Brett E Houk, et al.
Clinical Pharmacology and Therapeutics|June 18, 2005
A pharmacokinetic-pharmacodynamic model for the quantitative prediction of dofetilide clinical QT prolongation from human ether-a-go-go-related gene current inhibition dataDaniël M Jonker, Leslie A Kenna, Derek Leishman, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Clinical Pharmacology and Therapeutics|October 28, 2020
Model Informed Drug Development: Collaboration Through A Common FrameworkRichard J Anziano, Peter A Milligan
British Journal of Clinical Pharmacology|January 30, 2004
Assessment of the relative in vivo potency of the hydroxylated metabolite of darifenacin in its ability to decrease salivary flow using pooled population pharmacokinetic-pharmacodynamic dataThomas Kerbusch, Peter A Milligan, Mats O Karlsson
Antimicrobial Agents and Chemotherapy|December 17, 2008
Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studiesMats O Karlsson, Irja Lutsar, Peter A Milligan
British Journal of Clinical Pharmacology|March 7, 2002
A population pharmacokinetic analysis of sildenafil citrate in patients with erectile dysfunctionPeter A Milligan, Scott F Marshall, Mats O Karlsson
British Journal of Clinical Pharmacology|November 18, 2003
Population pharmacokinetic modelling of darifenacin and its hydroxylated metabolite using pooled data, incorporating saturable first-pass metabolism, CYP2D6 genotype and formulation-dependent bioavailabilityThomas Kerbusch, Ulrika Wählby, Peter A Milligan, et al.
British Journal of Clinical Pharmacology|September 18, 2004
Models for time-varying covariates in population pharmacokinetic-pharmacodynamic analysisUlrika Wählby, Alison H Thomson, Peter A Milligan, et al.
CPT: Pharmacometrics & Systems Pharmacology|July 14, 2023
Model-informed drug development of autologous CAR-T cell therapy: Strategies to optimize CAR-T cell exposure leveraging cell kinetic/dynamic modelingAnna M Mc Laughlin, Peter A Milligan, Cassian Yee, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|June 13, 2008
A non-parametric method to analyse time-course of effect in the absence of pharmacokinetic data: application to inhaled bronchodilatorsBalaji M Agoram, Peter A Milligan, Piet H van der Graaf
Cancer Chemotherapy and Pharmacology|July 23, 2015
Modeling and simulations relating overall survival to tumor growth inhibition in renal cell carcinoma patientsLaurent Claret, Francois Mercier, Brett E Houk, et al.
Clinical Pharmacology and Therapeutics|June 18, 2005
A pharmacokinetic-pharmacodynamic model for the quantitative prediction of dofetilide clinical QT prolongation from human ether-a-go-go-related gene current inhibition dataDaniël M Jonker, Leslie A Kenna, Derek Leishman, et al.
Pageof 2